Robertet Valuation
Is 0R7 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 0R7 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 0R7 (€952) is trading below our estimate of fair value (€1155.07)
Significantly Below Fair Value: 0R7 is trading below fair value, but not by a significant amount.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 0R7?
Key metric: As 0R7 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is 0R7's PE Ratio? | |
|---|---|
| PE Ratio | 21x |
| Earnings | €86.35m |
| Market Cap | €1.81b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 2.6x |
| Enterprise Value/EBITDA | 13.3x |
| PEG Ratio | 2.6x |
Price to Earnings Ratio vs Peers
How does 0R7's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 28.5x | ||
WCH Wacker Chemie | 29.4x | 38.0% | €3.6b |
ACT AlzChem Group | 11.7x | 12.6% | €586.2m |
EVK Evonik Industries | 35.9x | 33.1% | €8.2b |
SY1 Symrise | 36.9x | 12.6% | €14.5b |
0R7 Robertet | 21x | 8.0% | €1.8b |
Price-To-Earnings vs Peers: 0R7 is good value based on its Price-To-Earnings Ratio (21x) compared to the peer average (28.5x).
Price to Earnings Ratio vs Industry
How does 0R7's PE Ratio compare vs other companies in the European Chemicals Industry?
| 2 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 2 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: 0R7 is expensive based on its Price-To-Earnings Ratio (21x) compared to the European Chemicals industry average (17.1x).
Price to Earnings Ratio vs Fair Ratio
What is 0R7's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 21x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 0R7's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | n/a | €1,096.67 0% | 4.1% | €1,150.00 | €1,040.00 | n/a | 3 |
| Nov ’25 | n/a | €1,096.67 0% | 4.1% | €1,150.00 | €1,040.00 | n/a | 3 |
| Oct ’25 | n/a | €1,096.67 0% | 4.1% | €1,150.00 | €1,040.00 | n/a | 3 |
| Sep ’25 | n/a | €1,096.67 0% | 4.1% | €1,150.00 | €1,040.00 | n/a | 3 |
| Aug ’25 | n/a | €1,125.00 0% | 2.2% | €1,150.00 | €1,100.00 | n/a | 2 |
| Jul ’25 | n/a | €1,115.00 0% | 1.3% | €1,130.00 | €1,100.00 | n/a | 2 |
| Jun ’25 | €888.00 | €1,115.00 +25.6% | 1.3% | €1,130.00 | €1,100.00 | n/a | 2 |
| May ’25 | n/a | €1,115.00 0% | 1.3% | €1,130.00 | €1,100.00 | n/a | 2 |
| Apr ’25 | n/a | €1,040.00 0% | 3.8% | €1,080.00 | €1,000.00 | n/a | 2 |
| Mar ’25 | n/a | €1,040.00 0% | 3.8% | €1,080.00 | €1,000.00 | n/a | 2 |
| Feb ’25 | n/a | €1,035.00 0% | 3.4% | €1,070.00 | €1,000.00 | n/a | 2 |
| Jan ’25 | €836.00 | €1,035.00 +23.8% | 3.4% | €1,070.00 | €1,000.00 | n/a | 2 |
| Dec ’24 | €762.00 | €1,035.00 +35.8% | 3.4% | €1,070.00 | €1,000.00 | n/a | 2 |
| Nov ’24 | €779.00 | €1,106.67 +42.1% | 9.5% | €1,250.00 | €1,000.00 | n/a | 3 |
| Oct ’24 | n/a | €1,160.00 0% | 7.8% | €1,250.00 | €1,070.00 | n/a | 2 |
| Sep ’24 | n/a | €1,165.00 0% | 7.3% | €1,250.00 | €1,080.00 | n/a | 2 |
| Aug ’24 | n/a | €1,165.00 0% | 7.3% | €1,250.00 | €1,080.00 | n/a | 2 |
| Jul ’24 | n/a | €1,165.00 0% | 7.3% | €1,250.00 | €1,080.00 | n/a | 2 |
| Jun ’24 | n/a | €1,165.00 0% | 7.3% | €1,250.00 | €1,080.00 | €888.00 | 2 |
| May ’24 | n/a | €1,165.00 0% | 7.3% | €1,250.00 | €1,080.00 | n/a | 2 |
| Apr ’24 | n/a | €1,165.00 0% | 7.3% | €1,250.00 | €1,080.00 | n/a | 2 |
| Mar ’24 | n/a | €1,175.00 0% | 6.4% | €1,250.00 | €1,100.00 | n/a | 2 |
| Feb ’24 | n/a | €1,150.00 0% | 8.7% | €1,250.00 | €1,050.00 | n/a | 2 |
| Jan ’24 | n/a | €1,150.00 0% | 8.7% | €1,250.00 | €1,050.00 | €836.00 | 2 |
| Dec ’23 | €833.00 | €1,150.00 +38.1% | 8.7% | €1,250.00 | €1,050.00 | €762.00 | 2 |
| Nov ’23 | €833.00 | €1,150.00 +38.1% | 8.7% | €1,250.00 | €1,050.00 | €779.00 | 2 |
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.
Discover undervalued companies
Central Asia Metals
UK£279.8m
Operates as a base metals producer.
9C3
UK£1.89
7D
-5.5%
1Y
-1.6%
Transcontinental
CA$1.4b
Engages in the flexible packaging business in Canada, the United States, Latin America, the United Kingdom, Australia, and New Zealand.
53L
CA$11.20
7D
-0.9%
1Y
54.5%
African Rainbow Minerals
R31.5b
Through its subsidiaries, operates as a diversified mining and minerals company in South Africa and Switzerland.
EB9
R8.40
7D
-5.1%
1Y
0.6%